{
    "nctId": "NCT05834686",
    "briefTitle": "HER2 Expression of CTC to Predict Response in HER2-positive Advanced Breast Cancer Patients Treated With ADC",
    "officialTitle": "An Exploratory Clinical Study of HER2 Expression of Circulating Tumor Cells : Predictive and Prognostic Value in HER2-positive Advanced Breast Cancer Patients Treated With ADC",
    "overallStatus": "RECRUITING",
    "conditions": "Breast Cancer",
    "studyType": "OBSERVATIONAL",
    "phase": "N/A",
    "allocation": "N/A",
    "primaryPurpose": "N/A",
    "enrollmentCount": 50,
    "primaryOutcomeMeasure": "Progression free survival(PFS)",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Has pathologically documented breast cancer that:\n\n  1. Is unresectable or metastatic\n  2. has confirmed HER2-positive expression defined as IHC 2+/ISH+ or IHC 3+\n  3. was previously treated with trastuzumab and taxane in the advanced setting or progressed within 6 months after neoadjuvant or adjuvant treatment involving a regimen including trastuzumab and taxane\n* Has adequate cardiac, bone marrow, renal, hepatic and blood clotting functions\n* Receives anti-HER2 ADC treatment\n* Life expectancy \\> 3 months\n* Evidence of measurable or evaluable disease (RECIST 1.1 criteria)in the 28 days before selection\n* ECOG \u22642\n\nExclusion Criteria:\n\n* Has uncontrolled or significant cardiovascular disease\n* Has history of (noninfectious) interstitial lung disease (ILD)/pneumonitis that required steroids, has current ILD/pneumonitis, or suspected ILD/pneumonitis that cannot be ruled out by imaging at screening\n* Has any medical history or condition that per protocol or in the opinion of the investigator is inappropriate for the study",
    "sex": "FEMALE",
    "minimumAge": "N/A",
    "stdAges": "CHILD, ADULT, OLDER_ADULT"
}